John Rose

Copolymer 1 reduces relapse rate and improves disability in relapsing‐remitting multiple sclerosis

K. P. Johnson, Benjamin Brooks, J. A. Cohen et al. · Neurology · 1995 · 1.9K citations

Pharmacy, Neurology, Pharmacotherapy +15

Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability

K. P. Johnson, Benjamin Brooks, J. A. Cohen et al. · Neurology · 1998 · 512 citations

Pharmacy, Pharmacology, Pharmacotherapy +12

Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta

Daniel Wynn, Michael D. Kaufman, Xavier Montalbán et al. · The Lancet Neurology · 2010 · 300 citations

Life Sciences, Neurology, Pharmacotherapy +10

Effect of Nonmyeloablative Hematopoietic Stem Cell Transplantation vs Continued Disease-Modifying Therapy on Disease Progression in Patients With Relapsing-Remitting Multiple Sclerosis

Richard K. Burt, Roumen Balabanov, Joachim Burman et al. · JAMA · 2019 · 300 citations · Full text

Medicine, Neurology, Cell Therapy +14

Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: a phase I/II study

Richard K. Burt, Yvonne Loh, Bruce A. Cohen et al. · The Lancet Neurology · 2009 · 278 citations

Life Sciences, Hematology, Immunology +14